Thera-SAbDab

ZENOCUTUZUMAB

>   Structural Summary
TherapeuticZenocutuzumab
Target 1ERBB3
Heavy Chain 1QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS
Light Chain 1DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK
100% seqID Fv 1 Structure5o4o [Fvs: BA], 5o7p [Fvs: BA]
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2ERBB2
Heavy Chain 2QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS
Light Chain 2DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK
100% seqID Fv 2 Structure5o4g [Fvs: BA]
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Metadata
FormatBispecific mAb
IsotypeG1
Highest Clinical Trial (Jan '20)Phase-II
Estimated Status (Jan '20)Active
Recorded Developmental TechnologyGlymaxX Technology
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedMerus
Conditions Approvedna
Conditions ActiveBreast cancer, Colorectal cancer, Gastric cancer, Non-small cell lung cancer
Conditions DiscontinuedEndometrial cancer, Ovarian cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]